Topical Tranexamic Acid (TXA) in Hip Fractures

Inclusion Criteria: All of the following criteria must be met to be eligible: 1. 18 years of age or older 2. Diagnosis of hip fracture (Intracapsular, Intratrochanteric or Subtrochanteric) requiring surgical repair 3. Patient/surrogate decision maker provide signed informed consent Exclusion Criteria: Participants cannot be included in this study if any of the following criteria apply: 1. Patient has documented renal failure with glomerular filtration rate of \<30ml/min/1.73m2 2. Documented allergy to tranexamic acid 3. Current use of hormone replacement therapy 4. Acquired disturbances of colour vision 5. Refusal of blood products 6. Pre-operative use of anticoagulant therapy (Coumadin, heparin \< 5 days of surgery, fibrinolytic disorders requiring intraoperative anti-fibrinolytic treatment) 7. Coagulopathy (pre-operative platelet count \<150,000/mm3, International Normalized Ratio (INR) \>1.4, prolonged Partial Thromboplastin Time (PTT) \>1.4x normal) 8. Hematuria 9. Acute coronary syndrome within 6 weeks of fracture 10. Any history of venous thromboembolism 11. Any intraoperative surgical/medical/anesthetic complications i.e.: myocardial infarction or neurovascular injury occurring prior to application of the tranexamic acid 12. Pregnant or lactating 13. Any major medical or psychiatric disorder that in the opinion of the investigator, might prevent the subject from completely participating in the study or interfere with the interpretation of the study results 14. Unable/unwilling to provide informed consent